Carcinogenicity And Oncogenicity of Precursor/Progenitor Stem Cells of the Xenogeneic Origin: The Balb/C-3t3 Cell Transformation Assay
SSP Modern Pharmacy and Medicine · 2025
DOI: 10.53933/61x4gw93 ↗Kurz gefasst
Fachartikel in der Zeitschrift SSP Modern Pharmacy and Medicine, 2025. Verfasst von Mike K.S. Chan und 11 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Stem cell-based therapies represent a transformative advancement in regenerative medicine, offering unprecedented opportunities to restore, replace, or regenerate damaged tissues and organs. Among these, xenogeneic cell therapy—utilizing cells derived from non-human animal sources—has shown therapeutic potential in both preclinical and early clinical settings. Functional improvements have been demonstrated with xenogeneic hepatocytes, pancreatic islet cells, and neural progenitors, highlighting their promise for treating organ dysfunction and degenerative conditions. However, concerns remain regarding the oncogenic risk associated with stem cell-based interventions, particularly those involving xenogeneic sources. To address these concerns, we employed the BALB/c 3T3 Cell Transformation Assay (BALB-CTA), a validated in vitro model replicating key stages of carcinogenesis, to evaluate the tumorigenic potential of various xenogeneic progenitor stem cell cultures. Progenitor cells from multiple tissue lineages were tested for their ability to induce malignant transformation, as evidenced by the formation of morphologically aberrant foci in BALB/c-3T3 cells. While the assay reliably detected transformation with known carcinogens such as 3-methylcholanthrene (MCA) and 12-O-tetradecanoylphorbol-13-acetate (TPA), none of the xenogeneic progenitor cell cultures exhibited tumor-initiating or promoting activity. Additionally, no lineage-specific differences were observed, indicating a consistent safety profile across different progenitor cell types. These findings support the non-carcinogenic nature of xenogeneic progenitor cell therapies in vitro and provide important preclinical evidence supporting their safety in regenerative medicine applications.
Zitieren
APA
Chan, M. K., Wong, M. B., Pan, S. Y., Chernykh, V., Shyshkina, N., Yemeliyanova, M., Klokol, D., Nishkumai, O., Alvin, G., Kobzev, O., Dubynska, S., & Lakey, J. (2025). Carcinogenicity And Oncogenicity of Precursor/Progenitor Stem Cells of the Xenogeneic Origin: The Balb/C-3t3 Cell Transformation Assay. SSP Modern Pharmacy and Medicine. https://doi.org/10.53933/61x4gw93
Vancouver
Chan MK, Wong MB, Pan SY, Chernykh V, Shyshkina N, Yemeliyanova M, et al. Carcinogenicity And Oncogenicity of Precursor/Progenitor Stem Cells of the Xenogeneic Origin: The Balb/C-3t3 Cell Transformation Assay. SSP Modern Pharmacy and Medicine. 2025. doi:10.53933/61x4gw93
BibTeX
@article{Chan2025,
author = {Chan, Mike K.S. and Wong, Michelle B.F. and Pan, Shing Yi and Chernykh, Volodymyr and Shyshkina, Nataliia and Yemeliyanova, Margaryta and Klokol, Dmytro and Nishkumai, Olha and Alvin, Glen and Kobzev, Oleg and Dubynska, Svitlana and Lakey, Jonathan},
title = {Carcinogenicity And Oncogenicity of Precursor/Progenitor Stem Cells of the Xenogeneic Origin: The Balb/C-3t3 Cell Transformation Assay},
journal = {SSP Modern Pharmacy and Medicine},
year = {2025},
doi = {10.53933/61x4gw93}
}
EUVIMED